共 247 条
[1]
Galie N(2016)2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J 37 67-119
[2]
Humbert M(2012)An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry Chest 142 448-456
[3]
Vachiery J-L(2017)Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Eur Respir J 50 1700740-1744
[4]
Gibbs S(1994)Survival in primary pulmonary hypertension. Validation of a prognostic equation Circulation 89 1733-203
[5]
Lang I(2005)New predictors of outcome in idiopathic pulmonary arterial hypertension Am J Cardiol 95 199-2708
[6]
Torbicki A(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 n71-394
[7]
Benza RL(1999)Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 2693-301
[8]
Miller DP(2011)Grade guidelines: 1. Introduction—grade evidence profiles and summary of findings tables J Clin Epidemiol 64 383-1123
[9]
Barst RJ(1996)A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 296-1502
[10]
Badesch DB(2001)Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study Lancet 358 1119-329